Abstract: A drug and device combination system used in a method for treatment of patients suffering from severe and oral corticosteroid-dependent asthma and other respiratory diseases requiring a treatment with orally administered steroids. The method for administration of the inhalable corticosteroid by a flow rate and volume regulated inhalation. The combination system of the inhalable corticosteroid and the device for regulating flow rate and volume of the inhalable corticosteroid and thus achieving delivery of said inhalable corticosteroid into the small airways of the lungs. The individually programmable device that assures safe and reproducible corticosteroid delivery compliant with treatment protocol.

Abstract: The invention provides an inhalation device comprising a base unit, a mouthpiece, and an aerosol head. The base unit comprises an air inlet, an air outlet opening, a groove for receiving the mouthpiece, and key lock member(s). The mouthpiece comprises a first segment, comprising an air inlet opening and a lateral opening for receiving an aerosol generator, the first segment being insertable into the groove of the base unit, and a second segment comprising an aerosol outlet. The aerosol head comprises an aerosol generator, a liquid reservoir, and key lock member(s) complementary to the key lock member(s) of the base unit. The base unit, mouthpiece and aerosol head are connectable with one another such that when engaging the members of the key lock with the complementary members, the aerosol generator is inserted into the lateral opening of the mouthpiece.

Abstract: A device for the flow rate limitation at low differential pressures, in particular for the limitation of the inhalation volume flow during the inhalation of therapeutic aerosols, comprising a housing with at least an inlet opening, at least an outlet opening and a flow channel arranged therebetween, wherein the flow channel is restricted by a flexible wall extending along the flow channel, characterized in that the flexible wall has a control area of less than 100 mm2.

Abstract: Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of the invention is the significant reduction in corticosteroid-related adverse effects.

Abstract: The present invention is directed to the administration of aerosolized particles to specific area of the lungs, and in particular to the targeted delivery of aerosolized pharmaceutical formulations to a specific area of the lungs. More specifically, the present invention relates to devices and methods for depositing aerosolized particles to a specific area of the lungs by regulating aerosolizing parameters of the device. The present invention also relates to devices, systems and methods for disease management, where the aerosolizing parameters are adjusted based on monitoring at least one health parameter.

Abstract: The invention relates to the use preferably of at least one active ingredient for the prophylaxis or therapy of a viral disease, wherein this active ingredient inhibits at least one component of the cellular signal transduction pathway for the activation of the transcription factor NF-kB such that virus multiplication is inhibited. The present invention relates furthermore to the local, preferably aerogenic, administration of the active ingredient according to the invention for inhibiting virus multiplication. The active ingredient according to the invention may be combined with at least one further antivirally effective substance for the prophylaxis or therapy of a viral disease.

Abstract: The present invention relates to a device for providing an aerosol flow, an air flow or both with at least a compressor for providing an air flow, a nebulization device for generating an aerosol flow and a mixing means for optionally mixing the aerosol flow with the air flow to provide a total flow, wherein the total flow is composed of the aerosol flow, the air flow or both. Further, the device comprises at least a first air channel between the compressor and the nebulization device, at least a second air channel between the compressor and the mixing means and an amplification means for increasing the air flow provided by the compressor.

Abstract: A method of treatment of cystic fibrosis and other pulmonary diseases identified by nitric oxide deficiency, comprising administration of a nebulized solution of citrulline and/or another nitric oxide precursor as an inhalable aerosol or an inhalable dry powder for targeted delivery into conducting and central airways. Citrulline or another nitric oxide precursor is formulated as a composition having predetermined limited volume, salinity, pH and osmolality. The composition is nebulized into an aerosol having a mass median aerodynamic diameter (MMAD) between 2 ?m and 6 ?m.

Abstract: Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of the invention is the significant reduction in corticosteroid-related adverse effects.

Abstract: The invention relates to a method of use of a composition comprising a salt of the o-acetylsalicylic acid with a basic amino acid for producing a pharmaceutical composition for the prophylaxis or treatment of viral infections of humans or of animals, in particular mammals and birds.

Abstract: The present invention relates to an improved controllable valve, in particular for an inhalation device, which, e.g., comprises a container for a predetermined aerosol volume, a means for disbursing an aerosol from an aerosol dispenser into the container and a control means that keeps the inhalation flow essentially constant during the entire inhalation. The control means comprises an either continuously or gradually controllable valve so as to limit the flow rate.

Abstract: The invention relates to a device for the flow rate limitation at low differential pressures, in particular for the limitation of the inhalation volume flow during the inhalation of therapeutic aerosols, comprising a housing with at least an inlet opening, at least an outlet opening and a flow channel arranged therebetween, wherein the flow channel is restricted by a flexible wall extending along the flow channel, characterised in that the flexible wall has a control area of less than 100 mm2.

Abstract: An inhalation device may include a control and an air pump that is connected to the control. The air pump is controlled by the control such that the air pump supplies an inhalation flow, or inhalation volume or both according to a predetermined time course to a nebulizer connected to the air pump. The inhalation flow, inhalation volume or both is controlled by controlling the air pump, rather than by using valves.

Abstract: A method for treatment of severe and uncontrollable asthma by providing means for delivery of high doses of a suitable inhalable corticosteroid directly to the small airways of the lower lungs with substantial decrease in need for simultaneous administration of oral corticosteroids and with a significant reduction in undesirable secondary side effects in an oropharyngeal area. The method utilizes devices allowing individualization of treatment parameters in asthmatic patients having compromised breathing pattern due to severe and uncontrollable asthma.

Abstract: A device for the controlled inhalation of therapeutic aerosols comprises means providing individual patient parameters and/or aerosol parameters for the inhalation. The aerosol doses, such as the tidal volume and the respiratory flow, are individually adjusted on the basis of these individual parameters. Thus, the inhalation device may be individually adjusted to the patient to be treated.

Abstract: A method for treatment of patients with pulmonary diseases by providing an aerosolized combination of a methylxanthine and a topical steroid administered into a patient's conducting and central airways. The method utilizes a specific treatment protocol and a nebulizing system providing an aerosol having particles of a predetermined mass medial aerodynamic diameter (MMAD) delivered to the conducting and central lungs with overpressure and under controlled conditions.

Abstract: The invention relates to a component for an inhalation device comprising a first flow channel for inhalation, a second flow channel for exhalation, a mouthpiece forming a part of the first flow channel, a filter assigned to the second flow channel and a protection element which circumferentially surrounds the mouthpiece and is sealingly connected the mouthpiece at the end opposing the tip of the mouthpiece.

Abstract: The present invention is directed to methods, systems and computer-readable products for optimizing aerosol particle administration to the lungs. More specifically, the present invention relates to methods of tailoring inhaling maneuvers for aerosol particle administration using the subject's lung function data and to systems and computer-readable products carrying out such methods.

Abstract: The invention relates to the use of at least one caspase inhibitor, in particular a caspase-3 inhibitor, for preparing a pharmaceutical composition for the prophylaxis or therapy of a viral infection, in particular an infection with an RNA negative-strand virus, preferably an influenza infection, and to a test system for identifying suitable active substances.